Highly Efficient Three-Component Coupling Reaction Catalyzed by Gold Nanoparticles Supported on Periodic Mesoporous Organosilica with Ionic Liquid Framework

Babak Karimi,* Mohammad Gholinejad* and Mojtaba Khorasani *E-mail: <u>karimi@iasbs.ac.ir</u>andgholinejad@iasbs.ac.ir*

Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), P.O. Box 45195-1159, GavaZang, Zanjan, Iran

Table of Contents

1. Experimental Section		S3
1.1.	General	S 3
1.2.	Synthesis of ionic liquid precursor	S 3
1.3.	Synthesis of PMO containing ionic liquid, PMO-IL	S 3
1.4.	Preparation of Au@PMO-IL catalyst	S4
1.5.	General procedure for three-component coupling reaction of aldehyde, alkynes and amines	S4
		S4
1.6.	Typical procedure for recycling of catalyst	
2. Characterizations of catalyst		S 5
2.1.	FT-IR spectrum for PMO-IL and Au@PMO-IL (Fig 1S)	S 5
2.2.	Nitrogen adsorption-desorption isotherms (Fig. 2S)	S6
2.3.	TEM images	S7
2.4.	X-Ray photoelectron spectroscopy (XPS) spectra	S8
3. Characterizations of products		S9
4. C	opy of original ¹ H NMR and ¹³ C NMR of products	S15

1. Experimental Section

1.1. General

Sodium tetrachloro Aureate dihydrate (NaAuCl₄. $2H_2O$), Sodium Hydride 95%,Pluronic P123 (EO₂₀PO₇₀EO₂₀) andtetramethoxyorthosilicate (TMOS) were obtained from Aldrich. Imidazole and 3-chloropropyl-trimethoxysilan were purchased from Merck. Imidazole was crystalized in distilled CH₂Cl₂ and dried in desiccator under vacuumfor 3 daysbefore use.

1.2. Synthesis of ionic liquid precursor

The ionic liquid precursor was prepared using our last synthetic report with slightly modification^{1,2}. In a typical experiment, a suspension of sodium imidazolide in dry THF was prepared from reaction between dried imidazole (2 g)and NaH 95% (0.77 g) at a flame-dried two necks flask containingdry THF (60 ml) under argon atmosphere. 3-chloropropyl-trimethoxysilan (5.4 ml) was added to the mentioned stirred suspension and was refluxed for 30h. Then the reaction mixture is cooled to room temperature and the solvent removed by reduced pressure until the oil containing NaCl obtained. Then 3-chloropropyl-trimethoxysilan (5.4 ml) and dry toluene (60 ml) was added and refluxed for 48h. After cooling the reaction mixture to room temperature, toluene phase was separated by a clean syringe. Dry CH_2Cl_2 was added for removal of precipitated NaCl. Then, CH_2Cl_2 phase was transferred to another well-dried two necks flask. CH_2Cl_2 was removed by reduced pressure until ionic liquid and unreacted starting materials obtained. Finally, ionic liquid was washed by dry toluene for removal of starting materials.

1.3. Synthesis of PMO containing ionic liquid, PMO-IL

PMO-IL was synthesized according to our last methods, too.^{1,2}For a typical synthesis, a molar ratio 0.013 P123: 26.515 H₂O: 5.300KCl: 4.200 HCl: 1.000Si was used. The first, Pluronic P123 (1.67g) was dissolved in a mixture of H₂O (10.5g) and HCl, (2M, 46.14g). Then KCl (8.8 g) was added and system stirred until a homogenous solution obtained. A

pre-mixture of ionic liquid (0.86 g) and tetramethoxyorthosilicate (2.74g) in dry methanol was added to mentioned solution and stirred at 40 °C for 24 h. The resulting mixture was aged without stirring at 100 °C for 72h. The obtained PMO with surfactant was filtered and washed with deionized water, and dried at room temperature. The surfactant was extracted from the PMO-IL by a Soxhlet apparatus by using ethanol (100 ml) and *c*-HCl (3 ml). In a typical extraction, as synthesized PMO (1g) washed four times with acidic ethanols over 12 h.

1.4. Preparation of Au@PMO-IL catalyst

Au@PMO-IL was prepared based on simple ion exchange technique according to literature procedure.³ For atypical method, PMO-IL (0.5g, 1.0 mmol IL g⁻¹) was added to 10 ml of deionized water and sonicated for at least 10 min. NaAuCl₄, $2H_2O$ (0.034 g, 0.085 mmol) as Au precursor dissolved in 3 ml of deionized water and gradually was added to mentioned suspension and stirred at room temperature for 5 h. The resulted system was filtered and washed with deionized water (3×10 ml) and acetone (2×10 ml) respectively. The resulted yellow solid which is Au@PMO-IL dried at room temperature under vacuity. Loading of Au catalyst was detrmined 0.16 mmol Au g⁻¹ by atomic absorption spectroscopy (AAS).

1.5. General procedure for three-component coupling reaction of aldehyde, alkynes and amines

Au@PMO-IL (12 mg) was added to the mixture of aldehyde (1mmol), amine (1.2 mmol) and Alkyne (1.3mmol) in 5 ml CHCl₃. The reaction mixture was stirred for appropriate reaction time at room temperature. After completion of reaction, CHCl₃ was evaporated and crude product was purified using column chromatography on silica gel (EtOAc/*n*-hexane).

1.6. Typical procedure for recycling of catalyst

After completion of the reaction of p-tolualdehyde (1mmo) with phenyl acetylene (1.3 mmol) and piperidine (1.2 mmol), reaction mixture was centrifuged and solid

catalyst was washed with diethyl ether (2×5 mL), dried and reused for the similar reaction.

Reference

- [1] Karimi, B.; Elhamifar, D.; Clark, J. H.; Hunt, A. J. Chem. Eur. J. 2010, 16, 8047-8053
- [2] Karimi, B.; Elhamifar, D.; Clark, J. H.; Hunt, A. J. Org. Biomol. Chem. 2011,9. 7420-7426.
- [3] Karimi, B.; Ghoreishi-Nezhad, M.; Clark, J. H. Org. lett. 2005. 7. 625-628

2. Characterizations of catalyst




Fig. 1S. FT-IR spectrum for PMO-IL (blue) and Au@PMO-IL (red)




Fig.2S. Nitrogen adsorption-desorption isotherms (a) and pore size distributions (b) of the PMO-IL , Au@PMO-IL and recovered catalyst (re-Au@PMO-IL) after 3rd reaction cycle




Fig. 3S. TEM image of the fresh Au@PMO-IL




Fig. 4S. TEM image of the recovered Au@PMO-IL






Fig. 5S. XPS spectra for Au@PMO-IL (our active catalyst) and the reduced catalyst Au(0)@PMO-IL (Inactive catalyst)


2. Characterizations of products




1-(1,3-diphenylprop-2-ynyl) piperidine(table 2, entry1):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.70 (d, *J*=7.6 Hz, 2H), 7.58-7.56 (m, 2H), 7.43-7.32 (m, 6H), 4.86 (s, 1H), 2.64-2.612 (m, 4H), 1.69-1.62 (m, 4H), 1.51-1.48 (m, 2H); ¹³C NMR (400 MHz, CDCl₃) ppm 138.6, 131.8, 128.5, 128.3, 128.1, 128.0, 127.4, 123.3, 87.9, 86.1, 62.4, 50.5, 26.2, 24.4




4-(1,3-diphenylprop-2-ynyl)morpholine(table 2, entry 2):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.67 (d, *J*= 7.2 Hz, 2H), 7.56-7.54 (m, 2H), 7.42-7.32 (m, 6H), 4.83 (s. 1H), 3.87-3.73 (m, 4H), 2.67 (br, 4H); ¹³C NMR (400 MHz, CDCl₃) ppm 137.8, 131.8, 129.7, 128.6, 128.3, 128.2, 128.2, 127.8, 122.9, 88.5, 88.0, 67.1, 62.0, 49.8.




1-(3-phenyl-1-p-tolylprop-2-ynyl) piperidine(table 2, entry 3):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.58 (d,*J*= 8 Hz, 2H), 7.58 (br, 2H), 7.40-7.37 (m, 3H), 7.23 (d, *J*= 8 Hz, 2H), 4.81 (s, 1H), 2.64-2.63 (m, 4H), 2.42 (s, 3H), 1.69-1.62 (m, 4H), 1.51-1.49 (m, 2H); ¹³CNMR (400 MHz, CDCl₃) ppm 137.1, 135.6, 131.8, 128.8, 128.5, 128.3, 128.0, 123.4, 87.6, 86.4, 62.1, 50.7, 26.2, 24.5, 21.1.




4-(3-phenyl-1-p-tolylprop-2-ynyl)morpholine (table 2, entry 4):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.60 (br, 2H), 7.59 (d, *J*= 8 Hz, 2H), 7.40-7.39 (m, 3H), 7.25 (d, *J*= 8 Hz, 2H), 4.83 (s, 1H), 3.84-3.79 (m, 4H), 2.75- 2.67 (m, 4H), 2.43 (s, 3H); ¹³CNMR (400 MHz, CDCl₃) ppm 137.5, 134.9, 131.8, 129.0, 128.6, 128.3, 128.2, 123.1, 88.3, 86.4, 67.2, 61.8, 49.9, 21.2.




4-(3-phenyl-1-(thiophen-2-yl)prop-2-ynyl)morpholine (table 2, entry 5): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.575-7.54 (m, 2H), 7.38-7.37 (m, 3H), 7.33 (d, *J*= 5,2 Hz, 1H), 7.28 (d, *J*= 5,2 Hz, 1H), 7.01 (dd, *J*₁=*J*₂= 5.2 Hz, 1H), 5.04 (s, 1H), 3.84-3.75 (m, 4H), 2.78-2.67 (m, 4H); ¹³C NMR (400 MHz, CDCl₃) ppm 142.8, 131.8, 128.4, 128.3, 126.4, 126.3, 125.8, 122.6, 87.6, 84.2, 67.1, 57.8, 49.6.




1-(3-phenyl-1-(thiophen-2-yl)prop-2-ynyl) piperidine (table 2, entry 6): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.56 (m, 2H), 7.38-7.37 (m, 3H), 7.33 (d, *J*= 4.8 Hz, 1H), 7.27 (m, 1H), 7.01 (dd, *J*₁=*J*₂=3.6 Hz, 1H), 5.04 (s, 1H), 2.71-2.64 (m, 4H), 1.73-1.62 (m, 4H), 1.52- 1.49 (m, 2H); ¹³C NMR (400 MHz, CDCl₃) ppm 144.0, 131.9, 128.3, 128.2, 126.2, 125.8, 125.4, 123.0, 86.9, 85.3, 58.2, 50.6, 26.2, 24.4.




1-(1-(naphthalen-1-yl)-3-phenylprop-2-ynyl)piperidine (table 2, entry 7): ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.58 (d, *J*= 8.4 Hz, 1H), 8.11 (d, *J*= 7.2 Hz, 1H), 7.99 (d, *J*= 8 Hz, 1H), 7.94(d, *J*= 8.4 Hz, 1H), 7.73-7.58 (m, 5H), 7.49-7.46 (m, 3H), 5.60 (s, 1H), 2.82-2.80 (m, 4H), 1.74-1.39 (m, 6H); ¹³CNMR (400 MHz, CDCl₃) ppm 134.3, 134.2, 132.1, 131.9, 128.7, 128.5, 128.4, 128.2, 127.0, 125.9, 125.7, 125.1, 124.9, 123.1, 88.7, 86.0, 60.6, 50.8, 26.4, 24.7.




1-(3-phenyl-1-m-tolylprop-2-ynyl)piperidine (table 2, entry 8):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.63-7.61 (m, 2H), 7.53 (br, 2H), 7.43-7.40 (m, 3H), 7.35 (t, *J*= 7.6 Hz, 1H), 7.20 (d, *J*= 7.6 Hz), 4.85 (s, 1H), 2.69-2.66 (m, 4H), 2.48 (s, 3H), 1.72-1.68 (m, 4H), 1.56-1.37 (m, 2H); ¹³CNMR (400 MHz, CDCl₃) ppm 138.6, 137.7, 131.9, 129.3, 128.3, 128.3, 128.0, 128.0, 125.7, 123.5, 87.7, 86.4, 62.5, 50.8, 26.2, 24.5, 21.6.




1-(1-(2-chlorophenyl)-3-phenylprop-2-ynyl)piperidine (table 2, entry 9): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.81 (dd, *J*= 7.2, 1.6 Hz, 1H), 7.55 (dd, *J*= 7.6, 7.2 Hz, 2H), 7.42 (dd, *J*= 7.6, 1.2 Hz, 1H), 7.37-7.27 (m, 5H), 5.17 (s, 1H), 2.66 (br, 4H), 1.68-1.58 (m, 4H), 1.51-1.46 (m, 2H); ¹³CNMR (400 MHz, CDCl₃) ppm 136.4, 134.7, 131.8, 130.6, 129.8, 128.8, 128.3, 128.1, 126.2, 123.2, 87.7, 85.8, 59.3, 50.8, 26.2, 24.5.




4-(1-(2-chlorophenyl)-3-phenylprop-2-ynyl)morpholine (table 2, entry 10):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.21 (dd, *J*= 7.6, 2 Hz, 1H), 7.56-7.55 (m, 2H), 7.45 (d, *J*= 7.2 Hz, 1H), 7.38-7.27 (m, 5H), 5.19 (s, 1H), 3.79-3.72 (m. 4H), 2.73 (t, *J*= 4.4 Hz, 4H);¹³CNMR (400 MHz, CDCl₃) ppm 135.6, 134.7, 131.8, 130.5, 129.9, 129.1, 128.4, 128.3, 126.4, 122.8, 88.4, 84.7, 67.1, 58.9, 49.8.




1-(1-(furan-2-yl)-3-phenylprop-2-ynyl)piperidine (table 2, entry 11):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.54-7.52 (m, 2H),7.46 (br, 1H), 7.36-7.35 (m,3H), 6.51 (d, *J*= 2.8 Hz ,H),6.38 (d, *J*= 2 Hz ,1H), 4.91 (s, 1H), 3.85-3.76 (m, 4H), 2.62-2.60 (m, 4H), 1.71-1.60 (m, 4H), 1.49-1.46 (m, 2H);¹³C NMR (400 MHz, CDCl₃) ppm 151.6, 142.5, 131.8, 128.3,128.2, 122.9, 109.9, 109.2, 86.4, 83.8, 56.5, 50.5, 25.9, 24.3.




4-(1-(furan-2-yl)-3-phenylprop-2-ynyl)morpholine (table 2, entry 12): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.54-7.51 (m, 2H),7.43 (br, 1H), 7.37-7.36 (m, 3H), 6.54 (d, *J*= 2.8 Hz, 1H), 6.40-6.38 (m, 1H), 4.91 (s, 1H), 3.85-3.76 (m, 4 H), 2.73-2.66 (m, 4H); ¹³C NMR (400 MHz, CDCl₃) ppm 150.7, 142.9, 131.8, 128.5, 128.3, 122.5, 110.1, 109.7, 87.0, 82.8, 66.9, 56.1, 49.6.




4-(1-phenylnon-1-yn-3-yl)morpholine (table 2, entry 13):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.47 (br, 5H), 7.32 (br, 3H), 3.79 (br, 4H), 3.52 (t,*J*= 7.2 Hz, 1H), 2.77 (br, 2H), 2.61 (br, 2H), 1.75-1.73 (m, 2H), 1.58-1.51 (m, 2H), 1.35-1.30 (m, 6H), 0.93 (br, 3H); ¹³C NMR (400 MHz, CDCl₃) ppm 131.7, 128.2, 127.9, 123.2, 87.2, 86.1, 67.1, 58.1, 49.7, 32.9, 31.7, 29.0, 26.6, 22.6, 14.1.




1-(3-(4-methoxyphenyl)-1-phenylprop-2-ynyl) piperidine(table 2, entry 14): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.67 (d, *J*=7.6, 2H), 7.49 (d, *J*= 8.8 Hz, 2H), 7.39 (dd, *J*₁= *J*₂ = 7.6 Hz, 2H), 7.32 (*J*₁= *J*₂ = 7.6 Hz, 1H), 6.89 (d, *J*= 8.8 Hz, 2H), 4.81 (s, 1H), 3.85 (s, 3H), 2.59 (br, 4H), 1.66-1.60 (m, 4H), 1.49-1.47 (m. 2H); ¹³C NMR (400 MHz, CDCl₃) ppm 159.4, 138.8, 133.2, 128.4, 128.2, 127.0, 115.5, 113.9, 87.6, 84.5, 62.4, 55.3, 50.7, 26.2, 24.4.




1-(3-(4-methoxyphenyl)-1-p-tolylprop-2-ynyl)piperidine (table 2, entry 15): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.58 (d, *J*= 8 Hz, 2H), 7.52 (d, *J*= 8.8 Hz, 2H), 7.23 (d, *J*= 8 Hz, 2H), 6.91 (d, *J*= 8.8 Hz, 2H), 4.80 (s, 1H), 3.86 (s, 3H), 2.63 (br, 4H), 2.42 (s, 3H), 1.68-1.64 (m, 4H), 1.52-1.50 (m, 2H); ¹³CNMR (400 MHz, CDCl₃) ppm 159.4, 137.0, 135.8, 133.2, 128.7, 128.5, 115.6, 113.9, 87.4, 84.9, 62.2, 55.3, 50.7, 26.2, 24.5, 21.1.




4-(3-(4-methoxyphenyl)-1-phenylprop-2-ynyl)morpholine (table 2, entry 16): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.677 (d, *J*= 7.6 Hz, 2H), 7.49 (d, *J*= 8.8 Hz, 2H), 7.41(dd, *J*₁=*J*₂ = 7.6 Hz, 2H), 7.35 (dd, *J*₁= *J*₂ = 7.2Hz, 1H), 6.90 (d, J=8.8 Hz, 2H), 4.81 (s, 1H), 3.85 (s, 3H), 3.79-3.76 (m, 4H), 2.67 (br, 4H); ¹³C NMR (400 MHz, CDCl₃) ppm 159.6, 138.0, 133.2, 128.6, 128.2, 127.7, 115.1, 113.9, 88.3, 83.5, 67.2, 62.1, 55.3, 49.9.



1-(3-(4-methoxyphenyl)-1-(naphthalen-1-yl)prop-2-ynyl) piperidine (table 2, entry 17): ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.52 (d, *J*= 8.4 Hz, 1H), 8.04 (d, *J*= 7.6 Hz, 1H), 7.93 (d, *J*= 7.6 Hz, 1H), 7.88 (d, *J*= 8.4 Hz, 1H), 7.62-7.52 (m, 5H), 6.94 (d, *J*= 8.8 Hz, 2H), 5.52 (s, 1H), 3.86 (s, 3H), 2.74-2.73 (m, 4H), 1.66-1.37 (m, 6H); ¹³CNMR (400 MHz, CDCl₃) ppm 159.5, 134.5, 134.1, 133.2, 132.0, 128.5, 128.4, 126.9, 125.8, 125.6, 125.1, 124.8, 115.6, 114.0, 88.4, 84.4, 60.6, 55.3, 50.8, 26.3, 24.7.





1-(1-(4-methoxyphenyl)non-1-yn-3-yl)piperidine (table 2, entry 18): ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.38 (d, *J*= 8.4 Hz, 2H), 6.82 (d, *J*= 8.8 Hz, 2H), 3.78 (s, 3H), 3.47 (t, *J*= 6 Hz, 1H), 2.69 (br, 2H), 2.49 (br, 2H), 1.73-1.61 (m, 7H), 1.57-.146 (m, 3H), 1.39-1.32 (m, 7H), 0.92-0.89 (m, 3H); ¹³CNMR (400 MHz, CDCl₃) ppm 159.2, 133.0, 115.8, 113.7, 86.5, 85.3, 58.6, 55.1, 50.5, 33.5, 31.8, 29.1, 26.9, 26.2, 24.6, 22.6, 14.1.





4-(1-(4-methoxyphenyl)-5-phenylpent-1-yn-3-yl)morpholine(table 2, entry 19):¹H NMR (400 MHz, CDCl₃, ppm): δ 7.44 (d, *J*= 8.8 Hz, 2H), 7.34-7.25 (m, 5H), 6.89 (d, *J*= 8.8 Hz), 3.84 (s, 3H), 3.83-3.79 (m, 4H), 3.52 (t, *J*= 16 Hz , 1H), 2.98-2.91(m, 1H), 2.87-2.78 (m, 3H), 2.62-2.61 (m, 2H) 2.09-2.07 (m, 2H); ¹³C NMR (400 MHz, CDCl₃) ppm 159.4, 141.6, 133.1, 128.6, 128.4, 125.9, 115.3, 113.9, 86.4, 85.2, 67.2, 57.1, 55.3, 49.7, 34.6, 32.6.


3. Copy of original¹H NMR and¹³C NMR of products.





























S26

